Drag a card by its title · ⚙ to size, swap or remove

The company

Precision BioSciences, Inc.

DTIL · Nasdaq

Health CareBiotechnologyNot moving yet

DTIL stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 19.2% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 5
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $93K
Insider sales, 12 months: $897K
Officials’ trades on record: 0
Institutions holding: 93 (+19)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months6

Sale orders, 12 months11

Buyers · sellers3 · 4

Who	Did	Shares	Traded
Stanley FrankelDirector	bought	1,000at $6.00	28 Sep 2026filed 30 Sep 2026
Geno J. GermanoDirector	bought	2,609at $6.28	25 Sep 2026filed 29 Sep 2026
Melinda BrownDirector	bought	1,135at $6.27	25 Sep 2026filed 29 Sep 2026
J. Jefferson SmithChief Research Officer	sold	4,925at $3.84	18 Feb 2026filed 19 Feb 2026
Dario ScimecaGeneral Counsel and Secretary	sold	4,925at $3.84	18 Feb 2026filed 19 Feb 2026
John Alexander KellyChief Financial Officer	sold	8,149at $3.84	18 Feb 2026filed 19 Feb 2026
Michael AmorosoPresident and CEO	sold	20,559at $3.84	18 Feb 2026filed 19 Feb 2026
Michael AmorosoPresident and CEO	sold	34,799at $4.17	22 Jan 2026filed 22 Jan 2026
J. Jefferson SmithChief Research Officer	sold	10,200at $4.03	21 Jan 2026filed 22 Jan 2026
John Alexander KellyChief Financial Officer	sold	15,213at $4.03	21 Jan 2026filed 22 Jan 2026
Dario ScimecaGeneral Counsel and Secretary	sold	8,854at $4.03	21 Jan 2026filed 22 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders93+19 on the quarter

New · exited32 · 14

Reported value$137.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Aberdeen Group plcunchanged · filed 31 Jul 2026	2,230,178$17.5M	00.0%
Bleichroeder LPadded · filed 13 Aug 2026	2,018,190$15.9M	+355,690+21.4%
Octagon Capital Advisors LPreduced · filed 14 Aug 2026	1,350,000$10.6M	-886,732−39.6%
BOOTHBAY FUND MANAGEMENT, LLCadded · filed 14 Aug 2026	1,346,004$10.6M	+279,954+26.3%
BlackRock, Inc.added · filed 7 Aug 2026	1,172,873$9.2M	+973,112+487.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	1,116,241$8.8M	+205,501+22.6%
Lynx1 Capital Management LPreduced · filed 12 Aug 2026	950,466$7.5M	-34,647−3.5%
Driehaus Capital Management LLCreduced · filed 14 Aug 2026	946,707$7.4M	-48,664−4.9%
Empery Asset Management, LPreduced · filed 11 Aug 2026	776,093$6.1M	-1,192,786−60.6%
Affinity Asset Advisors, LLCadded · filed 13 Aug 2026	646,576$5.1M	+48,630+8.1%